The Stock Exchange of Hong Kong Limited has taken disciplinary action against two former directors of China Health Technology Group Holding Company Limited, previously known as China Bozza Development Holdings Limited (Stock Code: 1069). The Exchange issued a Director Unsuitability Statement and censured Mr. Wang Yue, a former executive director, and Ms. Tian Guangmei, a former independent non-executive director, deeming them unsuitable for any director or senior management roles within the company or its subsidiaries. This action follows their involvement in the approval and extension of loans totaling HK$138.3 million between 2015 and 2019, alongside their failure to cooperate with the Exchange's investigation. The disciplinary measures are solely applicable to the two individuals and not to the company or its other directors. The announcement was made on May 28, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。